OrthoPediatrics Corp. (NASDAQ:KIDS) Receives $34.14 Consensus Price Target from Analysts

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have received an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $34.1429.

Several research analysts have weighed in on the company. JMP Securities set a $35.00 price target on OrthoPediatrics and gave the stock a “market outperform” rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Citigroup reiterated a “market outperform” rating on shares of OrthoPediatrics in a research note on Friday, August 8th. Finally, BTIG Research decreased their price objective on shares of OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th.

OrthoPediatrics Trading Down 3.3%

OrthoPediatrics stock opened at $19.65 on Wednesday. The company has a market cap of $492.63 million, a price-to-earnings ratio of -10.98 and a beta of 1.06. The firm has a 50-day moving average of $20.90 and a 200-day moving average of $21.88. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. OrthoPediatrics has a one year low of $16.59 and a one year high of $33.14.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%.The business had revenue of $61.08 million for the quarter, compared to analyst estimates of $61.40 million. OrthoPediatrics has set its FY 2025 guidance at EPS. On average, equities analysts expect that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Insider Buying and Selling

In other OrthoPediatrics news, CFO Fred Hite purchased 5,076 shares of the stock in a transaction on Thursday, August 21st. The shares were purchased at an average price of $19.41 per share, with a total value of $98,525.16. Following the completion of the transaction, the chief financial officer directly owned 213,065 shares in the company, valued at $4,135,591.65. This represents a 2.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 32.70% of the company’s stock.

Institutional Trading of OrthoPediatrics

A number of hedge funds have recently made changes to their positions in the business. Los Angeles Capital Management LLC acquired a new position in shares of OrthoPediatrics during the 2nd quarter worth approximately $220,000. PDT Partners LLC acquired a new stake in OrthoPediatrics during the 1st quarter valued at $244,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after purchasing an additional 645 shares during the period. GAMMA Investing LLC increased its holdings in shares of OrthoPediatrics by 4,618.2% in the first quarter. GAMMA Investing LLC now owns 10,616 shares of the company’s stock valued at $261,000 after purchasing an additional 10,391 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of OrthoPediatrics in the second quarter valued at about $272,000. 69.05% of the stock is owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.